Nucleotide excision repair and anti-cancer chemotherapy

被引:30
作者
Reed, E [1 ]
机构
[1] NCI, Med Ovarian Canc Sect, Med Branch, Div Clin Sci, Bethesda, MD 20892 USA
关键词
DNA adduct; ERCC1; nucleotide excision repair; ovarian cancer; platinum compounds;
D O I
10.1023/A:1008016922425
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
DNA repair is an important effector of anti-cancer drug resistance. In recent years, it has become apparent that DNA repair is an extremely complex process. Processes within DNA repair that may contribute to one or more drug resistance phenotypes include; O-6-alkyltransferase activity, base excision repair, mismatch repair, nucleotide excision repair, and gene specific repair. Clearly, several of these processes may show increased activity within any single cell, or tumor, at any one time. This review attempts to touch briefly upon the question of the distinctions between each of these specific pathways: and then seeks to expand on nucleotide excision repair as a possible effector of cellular and clinical resistance to platinum-based anticancer therapy.
引用
收藏
页码:187 / 201
页数:15
相关论文
共 97 条
[1]  
Aebi S, 1996, CANCER RES, V56, P3087
[2]  
[Anonymous], CANC CHEMOTHERAPY BI
[3]   A PRELIMINARY RISK-BENEFIT ASSESSMENT OF PACLITAXEL [J].
BITTON, RJ ;
FIGG, WD ;
REED, E .
DRUG SAFETY, 1995, 12 (03) :196-208
[4]   FORMATION OF COVALENT COMPLEXES BETWEEN HUMAN O-6-ALKYLGUANINE-DNA ALKYLTRANSFERASE AND BCNU-TREATED DEFINED LENGTH SYNTHETIC OLIGODEOXYNUCLEOTIDES [J].
BRENT, TP ;
REMACK, JS .
NUCLEIC ACIDS RESEARCH, 1988, 16 (14) :6779-6788
[5]  
CITARDI M J, 1990, Proceedings of the American Association for Cancer Research Annual Meeting, V31, P410
[6]   EXPRESSION OF EXCISION REPAIR GENES IN NONMALIGNANT BONE-MARROW FROM CANCER-PATIENTS [J].
DABHOLKAR, M ;
BOSTICKBRUTON, F ;
WEBER, C ;
EGWUAGU, C ;
BOHR, VA ;
REED, E .
MUTATION RESEARCH, 1993, 293 (02) :151-160
[7]   DETERMINANTS OF CISPLATIN SENSITIVITY IN NONMALIGNANT NON-DRUG-SELECTED HUMAN T-CELL LINES [J].
DABHOLKAR, M ;
PARKER, R ;
REED, E .
MUTATION RESEARCH, 1992, 274 (01) :45-56
[8]  
DABHOLKAR M, 1995, ONCOL REP, V2, P209
[9]   ERCC1 AND ERCC2 EXPRESSION IN MALIGNANT-TISSUES FROM OVARIAN-CANCER PATIENTS [J].
DABHOLKAR, M ;
BOSTICKBRUTON, F ;
WEBER, C ;
BOHR, VA ;
EGWUAGU, C ;
REED, E .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1992, 84 (19) :1512-1517
[10]   MESSENGER-RNA LEVELS OF XPAC AND ERCC1 IN OVARIAN-CANCER TISSUE CORRELATE WITH RESPONSE TO PLATINUM-BASED CHEMOTHERAPY [J].
DABHOLKAR, M ;
VIONNET, J ;
BOSTICKBRUTON, F ;
YU, JJ ;
REED, E .
JOURNAL OF CLINICAL INVESTIGATION, 1994, 94 (02) :703-708